Used in cancer immunotherapy research to block the PVRIG immune checkpoint pathway, enhancing T-cell activation and anti-tumor immune responses. Investigated for potential in treating solid tumors, particularly in combination with other immune checkpoint inhibitors like anti-PD-1 or anti-TIGIT antibodies. Supports preclinical studies aimed at understanding immune regulation and developing novel therapeutic strategies.